Postmenopausal endometrial hyperplasia: role of danazol therapy.

Abstract

OBJECTIVES:

To confirm the effectiveness of danazol in the management of simple or complex endometrial hyperplasia without atypical features, as has been demonstrated previously.

METHODS:

Seventy-six patients affected by postmenopausal histologically-confirmed endometrial hyperplasia with uterine bleeding were submitted to danazol therapy at a dose of 400 mg/day for 3 consecutive months.

RESULTS:

After cessation of treatment, 82.8% of the patients (63/76 enrolled) showed a conversion of the hyperplasia into atrophic (65.8%), secretory (11.9%) or proliferative (4.2%) endometrium at the histological examination. Uterine bleeding disappeared, during the therapy, in 90% of the responders (59/63).

CONCLUSIONS:

Although 17.1% of the women had a persistence of the hyperplasia and 8.4% of the symptom-free women relapsed after 4 months of follow-up, this experience confirms the effectiveness of danazol therapy in hyperplastic endometrial lesions. Nevertheless, a study comparing danazol and progestin therapy is required.

• Authors: L Mariani, A Sedati, R Giovinazzi, R Sindico, G Atlante
• Journal: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (Int J Gynaecol Obstet) Vol. 44 Issue 2 Pg. 155-9 (Feb 1994) ISSN: 0020-7292 [Print] United States
• PMID: 7911101 (Publication Type: Journal Article)

Chemical References

• Danazol

Topics

• Aged
• Danazol (administration & dosage)
• Endometrial Hyperplasia (drug therapy, pathology)
• Endometrium (pathology)
• Female
• Follow-Up Studies
• Humans
• Middle Aged
• Postmenopause
• Recurrence